SGLT2 inhibition to target kidney aging
- PMID: 38803397
- PMCID: PMC11129592
- DOI: 10.1093/ckj/sfae133
SGLT2 inhibition to target kidney aging
Abstract
Anti-aging therapy is the latest frontier in the world of medical science, especially for widespread diseases such as chronic kidney disease (CKD). Both renal aging and CKD are characterized by increased cellular senescence, inflammation and oxidative stress. A variety of cellular signalling mechanisms are involved in these processes, which provide new potential targets for therapeutic strategies aimed at counteracting the onset and progression of CKD. At the same time, sodium-glucose co-transporter 2 inhibitors (SGLT2is) continuously demonstrate large beneficial effects at all stages of the cardiorenal metabolic continuum. The broad-spectrum benefits of SGLT2is have led to changes in several treatment guidelines and to growing scientific interest in the underlying working principles. Multiple mechanisms have been studied to explain these great renal benefits, but many things remain to be solved. With this in mind, we provide an overview of the experimental evidence for the effects of SGLT2is on the molecular pathway's ability to modulate senescence, aging and parenchymal damage, especially at the kidney level. We propose to shed some light on the role of SGLT2is in kidney care by focusing on their potential to reduce the progression of kidney disease across the spectrum of aging and dysregulation of senescence.
Keywords: SGLT2 inhibitors; aging; chronic kidney disease; molecular pathways; senescence.
© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.
Conflict of interest statement
All authors and co-authors declare no conflicts of interest.
Figures
![Figure 1:](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11129592/bin/sfae133fig1.gif)
![Figure 2:](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11129592/bin/sfae133fig2.gif)
![Figure 3:](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11129592/bin/sfae133fig3.gif)
Similar articles
-
Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.Cardiovasc Diabetol. 2023 Nov 16;22(1):316. doi: 10.1186/s12933-023-02023-y. Cardiovasc Diabetol. 2023. PMID: 37974185 Free PMC article. Review.
-
A real-world study on SGLT2 inhibitors and diabetic kidney disease progression.Clin Kidney J. 2022 Feb 16;15(7):1403-1414. doi: 10.1093/ckj/sfac044. eCollection 2022 Jul. Clin Kidney J. 2022. PMID: 35756732 Free PMC article.
-
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.Int J Mol Sci. 2022 Mar 26;23(7):3651. doi: 10.3390/ijms23073651. Int J Mol Sci. 2022. PMID: 35409011 Free PMC article. Review.
-
Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently.Diabetes Ther. 2022 May;13(5):889-911. doi: 10.1007/s13300-022-01242-y. Epub 2022 Mar 29. Diabetes Ther. 2022. PMID: 35349120 Free PMC article. Review.
-
SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort studies.Pharmacol Res. 2020 Nov;161:105175. doi: 10.1016/j.phrs.2020.105175. Epub 2020 Aug 26. Pharmacol Res. 2020. PMID: 32860942
References
Publication types
LinkOut - more resources
Full Text Sources